PMID- 37137746 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20231003 IS - 1873-5010 (Electronic) IS - 1569-1993 (Print) IS - 1569-1993 (Linking) VI - 22 IP - 4 DP - 2023 Jul TI - Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen. PG - 644-651 LID - S1569-1993(23)00121-2 [pii] LID - 10.1016/j.jcf.2023.04.017 [doi] AB - BACKGROUND: Changes in upper airway microbiota may impact early disease manifestations in infants with cystic fibrosis (CF). To investigate early airway microbiota, the microbiota present in the oropharynx of CF infants over the first year of life was assessed along with the relationships between microbiota and growth, antibiotic use and other clinical variables. METHODS: Oropharyngeal (OP) swabs were collected longitudinally between 1 and 12 months of age from infants diagnosed with CF by newborn screen and enrolled in the Baby Observational and Nutrition Study (BONUS). DNA extraction was performed after enzymatic digestion of OP swabs. Total bacterial load was determined by qPCR and community composition assessed using 16S rRNA gene analysis (V1/V2 region). Changes in diversity with age were evaluated using mixed models with cubic B-splines. Associations between clinical variables and bacterial taxa were determined using a canonical correlation analysis. RESULTS: 1,052 OP swabs collected from 205 infants with CF were analyzed. Most infants (77%) received at least one course of antibiotics during the study and 131 OP swabs were collected while the infant was prescribed an antibiotic. Alpha diversity increased with age and was only marginally impacted by antibiotic use. Community composition was most highly correlated with age and was only moderately correlated with antibiotic exposure, feeding method and weight z-scores. Relative abundance of Streptococcus decreased while Neisseria and other taxa increased over the first year. CONCLUSIONS: Age was more influential on the oropharyngeal microbiota of infants with CF than clinical variables including antibiotics in the first year of life. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Harris, J Kirk AU - Harris JK AD - Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, 13123 E. 16th Ave, B-395, Aurora, CO 80045, USA. Electronic address: Jonathan.Harris@cuanschutz.edu. FAU - Wagner, Brandie D AU - Wagner BD AD - Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Robertson, Charles E AU - Robertson CE AD - Department of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Stevens, Mark J AU - Stevens MJ AD - Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, 13123 E. 16th Ave, B-395, Aurora, CO 80045, USA. FAU - Lingard, Conor AU - Lingard C AD - Spartanburg Regional Healthcare Systems, Spartanburg, SC, USA. FAU - Borowitz, Drucy AU - Borowitz D AD - Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. FAU - Leung, Daniel H AU - Leung DH AD - Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. FAU - Heltshe, Sonya L AU - Heltshe SL AD - Cystic Fibrosis Foundation Therapeutic Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA. FAU - Ramsey, Bonnie W AU - Ramsey BW AD - Cystic Fibrosis Foundation Therapeutic Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA. FAU - Zemanick, Edith T AU - Zemanick ET AD - Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, 13123 E. 16th Ave, B-395, Aurora, CO 80045, USA. LA - eng GR - P30 DK089507/DK/NIDDK NIH HHS/United States GR - R01 DK095738/DK/NIDDK NIH HHS/United States GR - UL1 TR002535/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230501 PL - Netherlands TA - J Cyst Fibros JT - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society JID - 101128966 RN - 0 (RNA, Ribosomal, 16S) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Infant, Newborn MH - Infant MH - Humans MH - *Cystic Fibrosis/drug therapy MH - RNA, Ribosomal, 16S/genetics/analysis MH - *Microbiota MH - Trachea MH - Anti-Bacterial Agents/therapeutic use PMC - PMC10524365 MID - NIHMS1898343 OTO - NOTNLM OT - Bacterial load OT - Microbiome OT - Respiratory tract infections OT - Small subunit ribosomal RNA COIS- Declaration of Competing Interest Dr. Harris reports grants from the Cystic Fibrosis Foundation during the conduct of the study Dr. Wagner has nothing to disclose Dr. Robertson has nothing to disclose Dr. Lingard has nothing to disclose Dr. Borowitz has nothing to disclose Dr. Leung reports other from Merck, grants and other from Gilead, grants from Abbvie, grants from CF Foundation, outside the submitted work Dr. Heltshe has nothing to disclose Dr. Ramsey has nothing to disclose Dr. Zemanick reports grants from Cystic Fibrosis Foundation, NIH/NCATS, NIH/NHLBI, Savara and Calithera Biosciences during the conduct of the study, grants and fees from Vertex Pharmaceuticals, Cystic Fibrosis Foundation outside the submitted work EDAT- 2023/05/04 00:41 MHDA- 2023/09/11 06:42 PMCR- 2024/07/01 CRDT- 2023/05/03 21:55 PHST- 2023/01/17 00:00 [received] PHST- 2023/04/03 00:00 [revised] PHST- 2023/04/21 00:00 [accepted] PHST- 2024/07/01 00:00 [pmc-release] PHST- 2023/09/11 06:42 [medline] PHST- 2023/05/04 00:41 [pubmed] PHST- 2023/05/03 21:55 [entrez] AID - S1569-1993(23)00121-2 [pii] AID - 10.1016/j.jcf.2023.04.017 [doi] PST - ppublish SO - J Cyst Fibros. 2023 Jul;22(4):644-651. doi: 10.1016/j.jcf.2023.04.017. Epub 2023 May 1.